New Delhi, Apr 18 (PTI) The Competition Commission has cleared the proposed acquisition of a minority stake in BDR Pharmaceuticals International Pvt Ltd by Multiples Private Equity Fund III and other investors.

Under the transaction, the minority stake would be purchased by Multiples Private Equity Fund III, SRF Transnational Holdings Ltd, Balkrishna Industries Ltd, Dharmayug Investments Ltd, QRG Investments and Holdings Ltd, Nishant K Agarwal and Mallika Srinivasan, according to a notice filed with the watchdog.

Also Read | Sensex Sinks 1,172 Points; Infosys Records Worst Slump in Two Years.

BDR Pharmaceuticals is mainly into four therapeutic segments -- oncology, critical care, gynaecology, and neurology. It is engaged in manufacture and sale of active pharmaceutical ingredients as well as formulations, and contract development and manufacturing services.

In a tweet on Monday, Competition Commission of India (CCI) said it has approved the "acquisition of minority stake of BDR Pharmaceuticals International Private Limited by Multiples Private Equity Fund III and certain other investors".

Also Read | Maharashtra Shocker: Minor Boy Found Dead in Pimpri Chinchwad; Cops Suspect Murder.

Deals beyond a certain threshold require approval from the CCI.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)